PARP1 regulates the genomic ribonucleotide processing activity of TOP1 to prevent the formation of toxic TOP1-DNA adducts and the associated mutations

Ribonucleotides are frequently incorporated into the genome during DNA replication and are normally removed by RNase H2. Alternatively, DNA topoisomerase 1 (TOP1) can process genomic ribonucleotides through two sequential cleavage events, generating a 2',3'-cyclic phosphate-terminated nick and, subsequently, a TOP1 cleavage complex (TOP1cc). In addition, TOP1cc formation can lead to 2- to 5-bp slippage deletions, recently identified as the ID4 cancer signature. Here, we show that human TOP1 is intrinsically mutagenic, with a tendency to undergo secondary cleavage and form TOP1 cleavage complexes. We further demonstrate that PARP1, a central single-strand break repair factor, suppresses TOP1 secondary cleavage, TOP1cc formation, and the resulting slippage mutations. This regulation requires PARP1 to interact with both TOP1 and the 2',3'-cyclic phosphate-terminated nick produced by the initial TOP1 cleavage. Notably, a PARP1 mutant defective in TOP1 interaction is partially impaired in restoring PARP inhibitor sensitivity in PARP1-knockout cells, suggesting that PARP inhibitor cytotoxicity may partly result from PARP1 trapping at 2',3'-cyclic phosphate-terminated nicks and blocking their processing by TOP1 and other factors. Together, these findings reveal a novel role for PARP1 in regulating TOP1-dependent ribonucleotide processing, thereby suppressing cancer-signature mutations and contributing to the mechanism of PARP inhibitor cytotoxicity.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-04-21
DOI
https://doi.org/10.64898/2026.04.16.719024
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PARP1 regulates the genomic ribonucleotide processing activity of TOP1 to prevent the formation of toxic TOP1-DNA adducts and the associated mutations

Quan Wang, Hengyao Niu, Qi Cao, Edward James Sarrain et al.
bioRxiv (Cold Spring Harbor Laboratory)
PARP inhibition in cancer therapy
article

PARP1 regulates the genomic ribonucleotide processing activity of TOP1 to prevent the formation of toxic TOP1-DNA adducts and the associated mutations

Quan Wang, Hengyao Niu, Qi Cao, Edward James Sarrain, Angel Caitlin Bondoy
article en

Abstract

Ribonucleotides are frequently incorporated into the genome during DNA replication and are normally removed by RNase H2. Alternatively, DNA topoisomerase 1 (TOP1) can process genomic ribonucleotides through two sequential cleavage events, generating a 2',3'-cyclic phosphate-terminated nick and, subsequently, a TOP1 cleavage complex (TOP1cc). In addition, TOP1cc formation can lead to 2- to 5-bp slippage deletions, recently identified as the ID4 cancer signature. Here, we show that human TOP1 is intrinsically mutagenic, with a tendency to undergo secondary cleavage and form TOP1 cleavage complexes. We further demonstrate that PARP1, a central single-strand break repair factor, suppresses TOP1 secondary cleavage, TOP1cc formation, and the resulting slippage mutations. This regulation requires PARP1 to interact with both TOP1 and the 2',3'-cyclic phosphate-terminated nick produced by the initial TOP1 cleavage. Notably, a PARP1 mutant defective in TOP1 interaction is partially impaired in restoring PARP inhibitor sensitivity in PARP1-knockout cells, suggesting that PARP inhibitor cytotoxicity may partly result from PARP1 trapping at 2',3'-cyclic phosphate-terminated nicks and blocking their processing by TOP1 and other factors. Together, these findings reveal a novel role for PARP1 in regulating TOP1-dependent ribonucleotide processing, thereby suppressing cancer-signature mutations and contributing to the mechanism of PARP inhibitor cytotoxicity.

bioRxiv (Cold Spring Harbor Laboratory)
Northwestern University (US), Indiana University Bloomington (US), Stony Brook University (US)
Openalex Percentile: Top 17%
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.